Dr. Reddy’s subsidiary Promius Pharma has announced that a Phase 2 study of its DFN-02 intranasal sumatriptan for the treatment of migraine met its primary endpoint, the proportion of subjects free of migraine pain at 2 hours post dose. After 2 hours, 43.8% of patients treated with DFN-02 experienced migraine pain relief compared to 22.5% of patients who received placebo.
The study also demonstrated that DFN-02 provided significantly better relief of other migraine symptoms, including nausea and sensitivity to light and sound, compared to placebo.
The DFN-02 formulation includes 10 mg sumatriptan and 0.2% 1-O-n-dodecyl-β-D-maltopyranoside, a permeation enhancer.
Read the Promius Pharma press release.
